Genetic correlates of in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor

Journal of Virology

Volumn 70, Issue 12, 1996, Pages 8270-8276

  Condra, Jon H ^a   Holder, Daniel J ^a   Schleif, William A ^a   Blahy, Olga M ^a   Danovich, Robert M ^a   Gabryelski, Lori J ^a   Graham, Donald J ^a   Laird, Donna ^a   Quintero, Julio C ^a   Rhodes, Audrey ^a   Robbins, Helen L ^a   Roth, Elizabeth ^a   Shivaprakash, Malathi ^a   Yang, Tao ^a   Chodakewitz, Jeffrey A ^a   Deutsch, Paul J ^a   Leavitt, Randi Y ^a   Massari, Ferdinand E ^a   Mellors, John W ^b   Squires, Kathleen E ^c   Steigbigel, Roy T ^d   Teppler, Hedy ^e   Emini, Emilio A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c University of Alabama at Birmingham   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE; PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ARTICLE; CROSS RESISTANCE; EVOLUTION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 10344263394     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.12.8270-8276.1996     Document Type: Article

References (43)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Bacheler, L., M. Alexander, B. Anton, R. Buckery, C. H. Chang, K. Gallagher, P. K. Jadhav, K. Logue, M. Paul, W. W. Wilkerson, and D. Winslow. 1995. Drug susceptibility and growth characteristics of constructed HIV's with defined mutations in the proteasc gene. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:64.
3. Bryant, M., D. Getman, M. Smidt, J. Marr, M. Clare, R. Dillard, D. Lansky, G. Decrescenzo, R. Heintz, K. Houseman, K. Reed, J. Stolzenbach, J. Talley, M. Vazquez, and R. Mueller. 1995. SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 39:2229-2234.
4. Byrnes, V. W., V. V. Sardana, W. A. Schleif, J. H. Condra, J. A. Waterbury, J. A. Wolfgang, W. J. Long, C. L. Schneider, A. J. Schlabach, B. S. Wolanski, D. J. Graham, L. Gotlib, A. Rhodes, D. L. Titus, E. Roth, O. M. Blahy, J. C. Quintero, S. Staszewski, and E. A. Emini. 1993. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1576-1579.
5. Chen, C. M., A. Saldivar, M. Turon, N. E. Wideburg, T. Robins, S. Vasavanonda, K. Stewart, C. Park, X. P. Kong, D. J. Kempf, D. Ho, J. Erickson, and D. W. Norbeck. 1994. Biochemical characterization of HIV-1 protease mutants resistant to A-77003, A-80987. J. Cell. Biochem. 18D:166.
6. Condra, J. H., et al. Unpublished data.
7. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 374:569-571.
8. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, J. Zhang, J. A. Chodakewitz, P. J. Deutsch, and E. A. Emini. 1995. Dynamics of acquired HIV-1 clinical resistance to the protease inhibitor MK-639. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:72.
9. Craig, J. C., I. B. Duncan, D. Hockley, C. Grief, N. A. Roberts, and J. S. Mills. 1991. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res. 16:295-305.
10. Craig, J. C., L. Whittaker, I. B. Duncan, and N. A. Roberts. 1993 In vitro resistance to an inhibitor of HIV proteinase (Ro 31-8959) relative to inhibitors of reverse-transcriptase (AZT and TIBO). Antiviral Chem. Chemother. 4:335-339.
11. Dianzani, F., G. Antonelli, O. Turriziani, E. Riva, G. Dong, and D. Bellarosa. 1993. In vitro selection of human-immunodeficiency virus type-1 resistant to Ro 31-8959 proteinase inhibitor. Antiviral Chem. Chemother. 4:329-333.
12. Dorsey, B. D., R. B. Levin, S. L. McDaniel, J. P. Vacca, J. P. Guare, P. L. Darke, J. A. Zugay, E. A. Emini, W. A. Schleif, J. C. Quintero, J. H. Lin, I. W. Chen, M. K. Holloway, P. Fitzgerald, M. G. Axel, D. Ostovic, P. S. Anderson, and J. R. Huff. 1994. L-735,524 - the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443-3451.
13. Eberle, J., B. Bechowsky, D. Rose, U. Hauser, K. Vonderhelm, L. Gurtler, and H. Nitschko. 1995. Resistance of HIV type-1 to proteinase inhibitor Ro 31-8959. AIDS Res. Hum. Retroviruses 11:671-676.
14. El-Farrash, M. A., M. J. Kuroda, T. Kitazaki, T. Masuda, K. Kato, M. Hatanaka, and S. Harada. 1994. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J. Virol. 68:233-239.
15. Ho, D. D., T. Toyoshima, H. M. Mo, D. J. Kempf, D. Norbeck, C. M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994 Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetrical protease inhibitor. J. Virol. 68:2016-2020.
16. Holland, B. S., and M. D. Copenhaver. 1987. An improved sequentially rejective Bonferroni test procedure. Biometrics 43:417-424.
17. Holm, S. 1979. A simple sequentially rejective Bonferroni test procedure. Scand. J. Statistics 6:65-70.
18. Jacobsen, H., M. Hänggi, M. Ott, I. B. Duncan, S. Owen, M. Andreoni, S. Vella, and J. Mous. 1996. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J. Infect. Dis. 173:1379-1387.
19. Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Krohn, I. B. Duncan, and J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase-inhibitor Ro 31-8959. Virology 206:527-534.
20. Kaplan, A. H., S. F. Michael, R. S. Wehbie, M. F. Knigge, D. A. Paul, L. Everitt, D. J. Kempf, D. W. Norbeck, J. W. Erickson, and R. Swanstrom. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91:5597-5601.
21. Kempf, D. J., C. Flentge, K. C. Marsh, E. McDonald, T. Robins, S. Vasavanonda, C. M. Chen, N. E. Wideburg, C. Park, X. P. Kong, J. Denissen, D. D. Ho, M. Markowitz, T. Toyoshima, M. K. Singh, J. Erickson, H. L. Sham, K. Stewart, B. E. Green, M. Turon, A. Saldivar, and D. W. Norbeck. 1994. Symmetry-based inhibitors of HIV protease - oral bioavailability and resistance emergence. J. Cell. Biochem. 18D:130.
22. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
23. Kim, E. E., C. T. Baker, M. D. Dwyer, M. A. Murcko, B. G. Rao, R. D. Tung, and M. A. Navia. 1995. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1181-1182.
24. King, R. W., S. Garber, D. L. Winslow, C. Reid, L. T. Bacheler, E. Anton, and M. J. Otto. 1995. Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chem. Chemother. 6:80-88.
25. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus proteasc is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
26. Markowilz, M., H. M. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
27. Miller, R. G. 1974. The jackknife - a review. Biometrika 61:1-15.
28. Mo, H., M. Markowilz, and D. D. Ho. 1995. Patterns of specific mutations in HIV-1 protease that confer resistance to a panel of protease inhibitors, p. 89. In Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections. American Society for Microbiology. Washington, D.C.
29. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
30. Mosteller, F., and J. W. Tukey. 1977. Data analysis and regression, p. 133-164. Addison Wesley, Reading, Mass.
31. Myers, G., S. Wain-Hobson, L. E. Henderson, B. Korber, K.-T. Jeang, and G. N. Pavlakis. 1993. Human retroviruses and AIDS 1993. Los Alamos National Laboratory, Los Alamos. N.Mex.
32. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, K. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
33. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P. F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
34. Saag, M. S., E. A. Emini, O. L. Laskin. J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, K. W. Anderson, F. E. Massari, and G. M. Shaw. 1993. A short-term clinical evaluation of L-697,661, a nonnucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
35. Schapiro, J. M., M. A. Winters, F. Stewart, B. Efron, J. Norris, M. J. Kozal, and T. C. Merigan. 1996. The effect of high-dose saquinavir on viral load and CD4 (+) T-cell counts in HIV-intected patients. Ann. Intern. Med. 124: 1039-1050.
36. Schmit, J.-C., L. Ruiz, B. Clotet, A. Raventos, J. Tor, J. Leonard, J. Desmyter, E. De Clerq, and A.-M. Vandamme. 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.
37. Searle, S. R. 1987. Linear models for unbalanced data, p. 241-325. John Wiley & Sons, New York.
38. Smith, T., and R. Swanstrom. Selection for high level resistance to HIV-1 protease inhibitors used in pairs. Antiviral Ther., in press.
39. Tisdale, M., R. E. Myers, B. Maschera, N. Parry, N. M. Oliver, and E. D. Blair. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.
40. Turriziani, O., G. Antonelli, H. Jacobsen, J. Mous, E. Riva, M. Pistello, and F. Dianzani. 1994. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol. 38:297-298.
41. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Coudra, L. Gotlib, M. K. Holloway, J. Lin, I. W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524 - an orally bioavailable human immunodeficiency virus type-1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
42. Vaillancourt, M., D. Irlbeck, and R. Swanstrom. 1995. Sequence analysis of viral RNA from patients on AZT-saquinavir double therapy (ACTG 229). J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:74.
43. Wong, Y. N., D. L. Burcham, P. L. Saxton, S. Erickson-Viitanen, M. F. Grubb, C. Y. Quon, and S. M. Huang. 1994. A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs. Biopharm. Drug Disp. 15:535-544.